Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8673442 | 0.95 | MEN1 (0.49) | MEN1KMT2AMAPTATML3MBTL1 | |
| SCHEMBL3838857 | 0.93 | MEN1 (0.47) | MEN1KMT2AMAPTATML3MBTL1 | |
| SCHEMBL7691355 | 0.93 | MEN1 (0.47) | MEN1KMT2AMAPTATML3MBTL1 | |
| Acetic Acid SCHEMBL888002 | 0.91 | MEN1 (0.49) | MEN1KMT2AMAPTATML3MBTL1 | |
| Acetic Acid SCHEMBL215134 | 0.89 | ATM (0.47) | MEN1KMT2AMAPTATML3MBTL1 | |
| SCHEMBL2731548 | 0.87 | MAPT (0.43) | MEN1KMT2AMAPTATML3MBTL1 | |
| SCHEMBL973726 | 0.87 | MAPT (0.43) | MEN1KMT2AMAPTATML3MBTL1 | |
| Acetic Acid SCHEMBL5604746 | 0.85 | MEN1 (0.46) | MEN1KMT2AMAPTATML3MBTL1 | |
| SCHEMBL371118 | 0.84 | MEN1 (0.40) | MEN1KMT2AMAPTATML3MBTL1 | |
| SCHEMBL10612416 | 0.83 | NAAA (0.44) | MEN1KMT2AMAPTATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999818-B2 | High molecular weight triarylamine compound comprising terphenyl structure in molecular main chain and organic electroluminescent element comprising said high molecular weight compound | HODOGAYA CHEMICAL CO., LTD. (JP) | 2024-06-04 | — | — | US | disclosed |
| US-11834421-B2 | Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2023-12-05 | — | — | US | disclosed |
| CN-111741948-B | Saturated ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | 日本烟草产业株式会社 | 2023-11-10 | — | — | CN | disclosed |
| EP-3760619-B1 | SATURATED RING-CONDENSED DIHYDROPYRIMIDINONE OR DIHYDROTRIAZINONE COMPOUND, AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2023-10-25 | — | — | EP | disclosed |
| US-20220209129-A1 | PYRIDINE-CARBONITRILE COMPOUND AND ELECTROLUMINESCENT DEVICE INCLUDING THE SAME | NATIONAL TSING HUA UNIVERSITY (TW) | 2022-06-30 | — | — | US | disclosed |
| CN-114644617-A | Cyanopyridine compound and electroluminescent device comprising the same | 郑建鸿 | 2022-06-21 | — | — | CN | disclosed |
| US-20220119355-A1 | SATURATED-RING-FUSED DIHYDROPYRIMIDINONE OR DIHYDROTRIAZINONE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2022-04-21 | — | — | US | disclosed |
| US-20210253785-A1 | HIGH MOLECULAR WEIGHT TRIARYLAMINE COMPOUND COMPRISING TERPHENYL STRUCTURE IN MOLECULAR MAIN CHAIN AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAID HIGH MOLECULAR WEIGHT COMPOUND | HODOGAYA CHEMICAL CO., LTD. (JP) | 2021-08-19 | — | — | US | disclosed |
| EP-3760619-A1 | SATURATED RING-CONDENSED DIHYDROPYRIMIDINONE OR DIHYDROTRIAZINONE COMPOUND, AND PHARMACEUTICAL USE THEREOF | Japan Tobacco Inc. (JP) | 2021-01-06 | — | — | EP | disclosed |
| EP-3184112-B1 | SYNTHETIC INTERMEDIATE OF 1-(2-DEOXY-2-FLUORO-4-THIO-ß-D-ARABINOFURANOSYL)CYTOSINE | FUJIFILM CORP (JP) | 2020-12-23 | — | — | EP | disclosed |
| CN-1100417-A | N-heteroaryl-n'-phenylurea derivatives, their production and use | NIHON NOHYAKU CO LTD (JP) | 1995-03-22 | — | — | CN | disclosed |
| US-5348933-A | Triazine substituted compounds | ISHIHARA SANGYO KAISHA, LTD. (JP) | 1994-09-20 | — | — | US | disclosed |
| EP-0613894-A1 | N-Heteroaryl-N'-phenylurea derivatives, their production and use | NIHON NOHYAKU CO., LTD. (JP) | 1994-09-07 | — | — | EP | disclosed |
| EP-0592306-A2 | 19F-MRI Contrast medium | TERUMO KABUSHIKI KAISHA (JP) | 1994-04-13 | — | — | EP | disclosed |
| US-5288727-A | Hydrazone compounds, processes for their production, intermediates useful for their production and pesticidal compositions containing them | ISHIHARA SANGYO KAISHA LTD. (JP) | 1994-02-22 | — | — | US | disclosed |
| CN-1077453-A | Substituted pyridinesulfonamide compound or its salt prepare its method and the weedicide that contains it | ISHIHARA SANGYO KAISHA (JP) | 1993-10-20 | — | — | CN | disclosed |
| EP-0562731-A1 | Substituted pyridinesulfonamide compounds or their salts, process for preparing the same, and herbicides containing the same | ISHIHARA SANGYO KAISHA, Ltd. (JP) | 1993-09-29 | — | — | EP | disclosed |
| EP-0540697-A1 | NOVEL SULFONYLUREAS | Novartis AG (CH) | 1993-05-12 | — | — | EP | disclosed |
| WO-1992016522-A1 | NOVEL SULFONYLUREAS | CIBA-GEIGY AG (CH) | 1992-10-01 | — | — | WO | disclosed |
| EP-0500111-A2 | Hydrazone compounds, processes for their production, intermediates useful for their production and pesticidal compositions containing them | ISHIHARA SANGYO KAISHA, LTD. (JP) | 1992-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220209129-A1 | PYRIDINE-CARBONITRILE COMPOUND AND ELECTROLUMINESCENT DEVICE INCLUDING THE SAME | ARL1, RCN1, AR | MEN1 582/4885KMT2A 1823/4885MAPT 2735/4885 |
| US-11834421-B2 | Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | RORC, RORB, RORA | MEN1 3985/4885KMT2A 1904/4885MAPT 1809/4885 |
| US-20220119355-A1 | SATURATED-RING-FUSED DIHYDROPYRIMIDINONE OR DIHYDROTRIAZINONE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | RORC, RORB, RORA | MEN1 3985/4885KMT2A 1904/4885MAPT 1809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.